 | ||||||||||||||||||||||||||||||||||||
 |
PASSION FOR IDEAS |
|||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
|
|
BIND BiosciencesBind Biosciences (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles. Leveraging its proprietary Medicinal Nanoengineering™ platform, BIND will produce best in class drugs by drastically enhancing the performance of development candidates or marketed drugs. BIND’s current development efforts focus on oncology, cardiovascular disorders, inflammatory disease and RNAi therapeutics. Lead program BIND-014 targets a surface protein upregulated in solid tumors and is planned to enter clinical development by end 2010.BIND was incorporated in 2007 in Cambridge, MA, based on the work of two pioneers in the field of therapeutic nanoparticles, Dr. Robert Langer (MIT) and Dr. Omid Farokhzad (Harvard Medical School).
October 27, 2011 BIND Announces New $47.25 Million Financing To Accelerate Multi-Product Pipeline April 6, 2011 BIND Biosciences Receives 2011 Edison Award February 23, 2011 BIND Biosciences named one of MIT's Technology Review 2011 TR50 - second year in a row February 11, 2011 BIND Biosciences featured in the London Times January 7, 2011 BIND Biosciences Initiates Phase 1 Clinical Study of BIND-014 June 29, 2010 BIND Biosciences Secures $12.4 Million Financing |
|
|
|
|||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||||||||||||
| partner of the European Tech Tour |  |
"The Endeavour Vision team has been very helpful to BIND on multiple levels. Their advice, contacts and support rank with the best." Scott Minick, CEO, BIND Biosciences |
||||||||||||||||||||||||||||||||||
what we look for
Olivier Valdenaire
Sven Lingjaerde